Literature DB >> 12957230

Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity.

Tim Karl1, Torsten Hoffmann, Reinhard Pabst, Stephan von Hörsten.   

Abstract

Dipeptidyl-peptidase IV (DPPIV/CD26) is involved in several physiological functions by cleavage of dipeptides with a Xaa-Pro or Xaa-Ala sequence of regulatory peptides such as neuropeptide Y (NPY). Cleavage of NPY by DPPIV results in NPY(3-36), which lacks affinity for the Y(1) but not for other NPY receptor subtypes. Among other effects, the NPY Y(1) receptor mediates anxiolytic-like effects of NPY. In previous studies with F344 rat substrains lacking endogenous DPPIV-like activity we found a reduced behavioral stress response, which might be due to a differential degradation of NPY. Here we tested this hypothesis and administered intracerebroventricularly two different doses of NPY (0.0, 0.2, 1.0 nmol) in mutant and wildtype-like F344 substrains. NPY dose-dependently stimulated food intake and feeding motivation, decreased motor activity in the plus maze and social interaction test, and exerted anxiolytic-like effects. More important for the present hypothesis, NPY administration was found to be more potent in the DPPIV-negative substrains in exerting anxiolytic-like effects (increased social interaction time in the social interaction test) and sedative-like effects (decreased motor activity in the elevated plus maze). These data demonstrate for the first time a differential potency of NPY in DPPIV-deficient rats and suggest a changed receptor-specificity of NPY, which may result from a differential degradation of NPY in this genetic model of DPPIV deficiency. Overall, these results provide direct evidence that NPY-mediated effects in the central nervous system are modulated by DPPIV-like enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957230     DOI: 10.1016/s0091-3057(03)00154-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats.

Authors:  Ajaykumar N Sharma; Ashish Pise; Jay N Sharma; Praveen Shukla
Journal:  Metab Brain Dis       Date:  2014-08-17       Impact factor: 3.584

3.  Interaction of NPY compounds with the rat glucocorticoid-induced receptor (GIR) reveals similarity to the NPY-Y2 receptor.

Authors:  Renu Sah; Steven L Parker; Sulaiman Sheriff; Katherine Eaton; Ambikaipakan Balasubramaniam; Floyd R Sallee
Journal:  Peptides       Date:  2007-01-22       Impact factor: 3.750

4.  Impaired daily glucocorticoid rhythm in Per1 ( Brd ) mice.

Authors:  Robert Dallmann; Chadi Touma; Rupert Palme; Urs Albrecht; Stephan Steinlechner
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2006-02-28       Impact factor: 1.836

5.  Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

Authors:  Daisuke Katagiri; Yoshifumi Hamasaki; Kent Doi; Koji Okamoto; Kousuke Negishi; Masaomi Nangaku; Eisei Noiri
Journal:  J Am Soc Nephrol       Date:  2013-10-03       Impact factor: 10.121

6.  Differential Regulation of Neuropeptide Y in the Amygdala and Prefrontal Cortex during Recovery from Chronic Variable Stress.

Authors:  Jennifer L McGuire; Lauren E Larke; Floyd R Sallee; James P Herman; Renu Sah
Journal:  Front Behav Neurosci       Date:  2011-09-15       Impact factor: 3.558

7.  Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease.

Authors:  Anne-Christine Plank; Fabio Canneva; Kerstin A Raber; Yvonne K Urbach; Julia Dobner; Maja Puchades; Jan G Bjaalie; Clarissa Gillmann; Tobias Bäuerle; Olaf Riess; Hoa H P Nguyen; Stephan von Hörsten
Journal:  Front Neurosci       Date:  2018-01-25       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.